Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193,679,354
-
Total 13F shares
-
26,281,827
-
Share change
-
-1,384,525
-
Total reported value
-
$26,537,879
-
Put/Call ratio
-
1.2%
-
Price per share
-
$1.01
-
Number of holders
-
44
-
Value change
-
-$13,148,563
-
Number of buys
-
25
-
Number of sells
-
27
Institutional Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q1 2020
As of 31 Mar 2020,
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) was held by
44 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
26,281,827 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, COWEN AND COMPANY, LLC, CITADEL ADVISORS LLC, MORGAN STANLEY, GOLDMAN SACHS GROUP INC, Advisor Group Holdings, Inc., VANGUARD GROUP INC, MILLENNIUM MANAGEMENT LLC, Hudson Bay Capital Management LP, and PRIMECAP MANAGEMENT CO/CA/.
This page lists
44
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.